SCHEMBL155702

SCHEMBL155702

CC(C)CCOCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.56
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NAAA Q02083 1/20 0.43
CYP2C19 P33261 1/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CTSB P07858 1/20 0.43
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TACR1 P25103 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14763820 1.00 TSHR (0.56) TSHRKDM4EALDH1A1HSD17B10TDP1
SCHEMBL16674306 0.89 TDP1 (0.41) TSHRKDM4EALDH1A1HSD17B10TDP1
SCHEMBL18616451 0.88 TSHR (0.52) TSHRALDH1A1TDP1L3MBTL1NAAA
SCHEMBL19750824 0.87 TSHR (0.47) TSHRTDP1L3MBTL1NAAACYP2C19
SCHEMBL28515540 0.86 TSHR (0.45) TSHRALDH1A1TDP1L3MBTL1NAAA
SCHEMBL16055690 0.85 L3MBTL1 (0.54) TSHRTDP1L3MBTL1
SCHEMBL10652311 0.85 L3MBTL1 (0.54) TSHRTDP1L3MBTL1
SCHEMBL10653320 0.85 L3MBTL1 (0.54) TSHRTDP1L3MBTL1
SCHEMBL28540750 0.84 PPARG (0.41) TSHRKDM4EALDH1A1HSD17B10TDP1
SCHEMBL10052098 0.84 TSHR (0.44) TSHRKDM4EALDH1A1HSD17B10CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-01-14 US claimed
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS DONG A SOCIO HOLDINGS CO LTD (KR) 2023-01-05 US claimed
US-10233337-B2 Charge-transporting varnish NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2019-03-19 US claimed
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
EP-2822050-B1 CHARGE-TRANSPORTING VARNISH NISSAN CHEMICAL IND LTD (JP) 2017-06-14 EP claimed
CN-104145348-B Charge-transporting varnish 日产化学工业株式会社 2017-03-08 CN claimed
US-20150053892-A1 CHARGE-TRANSPORTING VARNISH NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-02-26 US claimed
CN-104145348-A CHARGE-TRANSPORTING VARNISH NISSAN CHEMICAL IND LTD 2014-11-12 CN claimed
EP-0912505-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2001-10-24 EP claimed
EP-0912505-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-05-06 EP claimed
WO-1997049680-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-31 WO claimed
US-5554588-A IN WHICH AT LEAST HALF COMPRISES ETHERS, AROMATIC METHYL KETONES, ALCOHOLS, ESTERS AND SALICYLATES; DEODORANTS AND ACCEPTABLE FRAGRANCE LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1996-09-10 US claimed
US-6413925-B1 None US disclosed
EP-4136067-B1 ODORANTS AND COMPOSITIONS COMPRISING ODORANTS S H KELKAR AND COMPANY LTD (IN) 2026-04-15 EP disclosed
US-12545852-B2 Odorants and compositions comprising odorants S H KELKAR AND COMPANY LIMITED (IN) 2026-02-10 US disclosed
US-12540073-B2 Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor BRILLIANT LIGHT POWER, INC. (US) 2026-02-03 US disclosed
US-4002583-A Substrate coating composition OWENS-ILLINOIS, INC. (US) 1977-01-11 US disclosed
US-3984350-A Catalyst component comprising brown titanium trichloride STANDARD OIL COMPANY (INDIANA) (US) 1976-10-05 US disclosed
US-3933868-A Process for the preparation of 1,5- and 1,8-diamino-anthraquinone BAYER AKTIENGESELLSCHAFT (DT) 1976-01-20 US disclosed
US-3933867-A Process for the preparation of 1-aminoanthraquinone BAYER AKTIENGESELLSCHAFT (DT) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs MERTK, ERBB2, SRC TSHR 1878/4885KDM4E 1727/4885ALDH1A1 3115/4885
US-12545852-B2 Odorants and compositions comprising odorants ENY2, CDY1; CDY1B, CHRM5 TSHR 2944/4885KDM4E 1249/4885ALDH1A1 453/4885
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS MERTK, ERBB2, SRC TSHR 1878/4885KDM4E 1727/4885ALDH1A1 3115/4885
US-12540073-B2 Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor SCO2, SOD1, HAO2 TSHR 830/4885KDM4E 4214/4885ALDH1A1 3874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.